Sarepta Therapeutics (NASDAQ:SRPT) Shares Down 5% – Time to Sell?

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) was down 5% during mid-day trading on Monday . The company traded as low as $126.19 and last traded at $126.69. Approximately 135,497 shares changed hands during trading, a decline of 89% from the average daily volume of 1,241,097 shares. The stock had previously closed at $133.34.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the stock. Royal Bank of Canada reissued an “outperform” rating and set a $182.00 price objective on shares of Sarepta Therapeutics in a report on Monday, October 21st. Raymond James restated an “outperform” rating and set a $150.00 price objective on shares of Sarepta Therapeutics in a research note on Thursday, October 10th. Jefferies Financial Group began coverage on Sarepta Therapeutics in a research report on Monday, October 21st. They set a “buy” rating and a $165.00 price objective on the stock. Guggenheim boosted their target price on shares of Sarepta Therapeutics from $148.00 to $150.00 and gave the stock a “buy” rating in a report on Thursday, November 7th. Finally, Citigroup lowered their price target on shares of Sarepta Therapeutics from $176.00 to $160.00 and set a “neutral” rating on the stock in a report on Thursday, August 8th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, twenty have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Sarepta Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $175.55.

Sarepta Therapeutics Stock Performance

The firm’s 50 day simple moving average is $122.57 and its 200 day simple moving average is $131.40. The firm has a market capitalization of $12.04 billion, a price-to-earnings ratio of 100.81 and a beta of 0.77. The company has a debt-to-equity ratio of 0.93, a quick ratio of 3.03 and a current ratio of 3.84.

Institutional Investors Weigh In On Sarepta Therapeutics

Hedge funds have recently added to or reduced their stakes in the business. Wellington Management Group LLP raised its position in Sarepta Therapeutics by 32.3% during the third quarter. Wellington Management Group LLP now owns 2,726,613 shares of the biotechnology company’s stock valued at $340,527,000 after acquiring an additional 665,087 shares in the last quarter. Erste Asset Management GmbH acquired a new stake in shares of Sarepta Therapeutics during the 3rd quarter worth approximately $79,425,000. Janus Henderson Group PLC increased its holdings in shares of Sarepta Therapeutics by 14.2% during the 3rd quarter. Janus Henderson Group PLC now owns 4,358,511 shares of the biotechnology company’s stock valued at $544,408,000 after purchasing an additional 543,143 shares in the last quarter. Principal Financial Group Inc. boosted its holdings in Sarepta Therapeutics by 693.7% during the second quarter. Principal Financial Group Inc. now owns 363,011 shares of the biotechnology company’s stock worth $57,356,000 after buying an additional 317,277 shares in the last quarter. Finally, Soros Fund Management LLC acquired a new stake in Sarepta Therapeutics during the third quarter valued at $25,800,000. 86.68% of the stock is owned by hedge funds and other institutional investors.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.